Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Oncolys BioPharma Inc. specializes in developing innovative cancer therapies, particularly focusing on its lead product, the immunotherapy agent, T-cell receptor (TCR) therapy. The company operates primarily in Japan and is expanding its clinical trials internationally, leveraging its proprietary technology to enhance treatment efficacy in oncology.
Oncolys BioPharma's business model is centered around developing and commercializing novel cancer therapies. The company has a high gross margin due to the nature of biotechnology products, which can command premium pricing once approved. Its competitive advantage lies in its proprietary TCR technology, which aims to provide more targeted and effective treatment options compared to traditional therapies.
Progress in clinical trials for TCR therapy, particularly Phase II and III results
Regulatory approvals from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
Partnership announcements with larger pharmaceutical companies for co-development
Market sentiment towards biotechnology stocks, influenced by broader sector performance
Regulatory changes affecting drug approval processes in key markets
Technological disruption from competing therapies or treatment modalities
Emergence of new immunotherapy competitors with superior efficacy
Potential for larger pharmaceutical companies to outpace Oncolys in R&D
High cash burn rate with negative operating cash flow ($-1.9B) raises concerns about liquidity
Dependence on successful fundraising to sustain operations
low - The demand for cancer therapies is relatively inelastic to economic cycles, as healthcare spending remains a priority.
Moderate - Rising interest rates can increase the cost of capital for R&D funding, impacting the company's ability to finance clinical trials.
minimal - The company has a low debt-to-equity ratio (0.20), indicating limited reliance on external credit.
growth - Investors seeking high-risk, high-reward opportunities in the biotechnology sector.
high - The stock has exhibited significant volatility, evidenced by a 307.7% return over the past year.